This is a preview of subscription content, log in via an institution to check access.
Notes
Costs included those for outpatient visits, diagnostic testing and screening, hospital- and treatment-related costs, as well as lost productivity, premature death and formal and informal care.
Reference
Cicin I, et al. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective Health Economics Review : 28 Jun 2021. Available from: URL: https://doi.org/10.1186/s13561-021-00322-2
Rights and permissions
About this article
Cite this article
Lung cancer a substantial economic burden in Turkey. PharmacoEcon Outcomes News 882, 19 (2021). https://doi.org/10.1007/s40274-021-7853-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7853-2